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Available online 20 April 2017Diabetes is a leading cause of renal disease. Glomerularmesangial expansion and ﬁbrosis are hallmarks of diabet-
ic nephropathy and this is thought to be promoted by inﬁltration of circulating macrophages. Monocyte
chemoattractant protein-1 (MCP-1) has been shown to attract macrophages in kidney diseases. P2X7 receptors
(P2X7R) are highly expressed on macrophages and are essential components of pro-inﬂammatory signaling in
multiple tissues. Here we show that in diabetic patients, renal P2X7R expression is associated with severe
mesangial expansion, impaired glomerular ﬁltration (≤40ml/min/1.73 sq. m.), and increased interstitial ﬁbrosis.
P2X7R activation enhanced the release of MCP-1 in human mesangial cells cultured under high glucose condi-
tions. In mice, P2X7R-deﬁciency prevented glomerular macrophage attraction and collagen IV deposition; how-
ever, themore severe interstitial inﬂammation and ﬁbrosis often seen in human diabetic kidney diseaseswas not
modelled. Finally, we demonstrate that a P2X7R inhibitor (AZ11657312) can reduce renal macrophage accrual
following the establishment of hyperglycemia in amodel of diabetic nephropathy. Collectively these data suggest
that P2X7R activation may contribute to the high prevalence of kidney disease found in diabetics.ntre for Cardiov
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Diabetic kidney disease is becoming a global epidemic (Gross et al.,
2005) and is expected to increase in prevalence as the diabetic popula-
tion grows (Shaw et al., 2010). Diabetic nephropathy is a unique
predictor of mortality in both insulin-dependent and -independent dia-
betes (Afkarian et al., 2013; Groop et al., 2009). Antihypertensive,
antiproteinuric and blood-glucose lowering therapies are themainstays
of treatment. However, despite aggressive blood pressure management
(Gross et al., 2005; Parving et al., 1983) and hyperglycemic control (The
Diabetes Control and Complications Trial Research Group, 1993), most
diabetic patients progress to chronic kidney disease (CKD) and eventu-
ally end-stage renal failure.
Diabetic nephropathy is driven by mobilization of major inﬂamma-
tory cascades (Wada andMakino, 2013) that result in glomerular extra-
cellular matrix (ECM) deposition, basement membrane thickening,ascular Science,
rance Crescent,
access article undermesangial sclerosis, proteinuria and interstitial ﬁbrosis (Mason and
Wahab, 2003; Tervaert et al., 2010). Pro-inﬂammatory signaling may
begin in the glomerular mesangium (Gómez-Guerrero et al., 2005;
Savill et al., 1992). Exposure to a high glucose milieu can enhance
mesangial secretion of the monocyte chemoattractant protein-1
(MCP-1) resulting in macrophage accumulation and glomerulonephri-
tis (Ihm et al., 1998; Wada et al., 2000), leading ultimately to ﬁbrosis
(Zeisberg and Neilson, 2010). In diabetic patients, the ratio of MCP-1
to creatinine is a predictor of reduced glomerular ﬁltration rate (GFR)
and renal impairment (Tam et al., 2009).
Multiple adenosine-5′-triphosphate (ATP)-activated (P2X) recep-
tors and G-protein coupled purinergic (P2Y) receptors regulate MCP-1
secretion in cell models (Shieh et al., 2014; Stokes and Surprenant,
2007). There are seven P2X receptors that when activated by ATP, func-
tion as non-selective cation channels (Costa-Junior et al., 2011). The
P2X7 receptor (P2X7R) has a uniquely long carboxyl domain that inter-
acts with membrane pores such as pannexin-1 - to drive inﬂammation,
cell death, and tissue remodelling (Lister et al., 2007; Menzies et al.,
2015b). P2X7R is highly expressed on macrophages where it regulates
the maturation and release of cytokines (Ferrari et al., 2006), and on
mesangial cells where it promotes ECM expansion (Solini et al., 2014,
2005). P2X7R is also expressed on non-immune cells, including thosethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(Menzies et al., 2013).
Preclinical research has identiﬁed P2X7R as an attractive therapeutic
target in kidney diseases (Menzies et al., 2016; Solini et al., 2013).
However, it is not yet clear whether P2X7R activation regulates
human diabetic nephropathy or, speciﬁcally, if glomerular P2X7R acti-
vation underlies disease severity. In the present study P2X7R was
immunolocalized in renal biopsies from diabetic patients and assessed
against indicators of renal function and disease. Resident glomerular
cells facilitate the accrual of macrophages and so P2X7R-mediated pro-
inﬂammatory signaling was investigated in primary human mesangial
cells exposed to high glucose.We next investigatedwhether P2X7R-de-
ﬁciency protected against diabetic renal injury in a murine model. In a
ﬁnal experiment, we investigated the therapeutic potential of a P2X7R
inhibitor (P2X7Ri) following the establishment of hyperglycemia in a
rat model of diabetic nephropathy.
2. Materials and Methods
2.1. Human Biopsy Samples
Renal biopsy specimens were obtained from patients after informed
consent (local ethics committee approval; NRES Committee London -
West London&GTAC; 04/Q0406/25), and onlymaterials surplus to clin-
ical need were used. Thin basement membrane (TBM) biopsies served
as controls for diabetic nephropathy. TBM represents the carrier state
for autosomal recessive Alport Syndrome, in which there are mutations
in basement membrane collagen typically without renal impairment
(Savige et al., 2013). Parafﬁn sections were retrieved from the histology
archive at Hammersmith Hospital for 3 TBM patients and 30 diabetics
(19/30; 63% type II).
2.2. Immunohistochemistry
Primary sections were de-waxed through xylenes and graded alco-
hols to water. Heat-induced epitope retrieval (HIER) was used. Sections
were placed in boiling sodium citrate buffer (0.01M; pH 6.0) and trans-
ferred to a water bath (95 °C for 20 min). Sections were then cooled
under running water for 5 min and placed in phosphate-buffered saline
(PBS; Sigma-Aldrich, Poole, UK). Sectionswere incubated in 0.3% hydro-
gen peroxide in PBS (10 min) then washed in PBS 3 times for 5 min
each. Sections were incubated in either 10% dry powdered milk (Mar-
vel; Premier Foods, St Albans, UK) or 20% normal goat serum (Dako;
Carpinteria, CA, USA) in PBS for 30 min at room temperature.
Primary antibodies for P2X7R (APR-004, Alomone, RRID: AB_
2040068; 1:50 murine; 1:100 human), human CD68 (Clone KP-1,
Dako, RRID: AB_563621; 1:100), murine CD68 (Clone FA-11, Serotec,
RRID: AB_323909; 1:200) and collagen IV (Ab6586, Abcam, RRID: AB_
305584; 1:100) were reconstituted in PBS. Blocking solution was
tapped off the slide and residual solution blotted. Primary antibody
was applied at sufﬁcient volume to cover the section (typically 100–
200 μl). Slides were incubated in a covered, humidiﬁed staining cham-
ber for 1 h (or overnight for human P2X7R staining). Negative controls
comprised omission of primary antibody, addition of polyclonal normal
rabbit immunoglobulin at an equivalent concentration to the primary
antibody, and use of primary antibody pre-incubated with the cognate
immunizing peptide at a 1:1 ratio. Detection was performed by a com-
mercial system (EnVision; Dako, Carpinteria, CA, USA). Positive staining
appeared as brown deposits.
Glomerular macrophage (CD68+) number was counted for 20 glo-
meruli in each section and the mean value obtained. The same starting
point was used in each section and the ﬁrst 20 randomly encountered
glomeruli were included. Interstitial macrophage number was counted
for 5 randomly selected ﬁelds of view (×200 magniﬁcation) and the
mean value obtained. Glomeruli were outlined and area measured and
type IV collagen calculated as percentage stained area per glomerulararea. Fifteen glomeruli in each section were scored and the mean
value taken.
2.3. Primary Human Mesangial Cells
Primary human mesangial cells (pHMCs; Lonza Biologics, Slough,
UK) were cultured in a proprietary basal medium supplemented with
5% fetal calf serum (FCS) and gentamicin amphotericin-B (Sigma-Al-
drich, Poole, UK). Cells were grown at 37 °C in a humidiﬁed atmosphere
of 5% CO2.Mediumwas changed every 2–3 days. At 90–100% conﬂuence
cells were sub-cultured onto chamber slides (Nunc, Lab-Tek, Thermo
Fisher Scientiﬁc,Waltham,MA, USA) or 96-well plates (Nunc,Maxisorp,
Thermo Fisher Scientiﬁc). Viability of pHMCs cultured in the presence of
small molecule receptor inhibitors was assessed using a 3-(4,5-dimeth-
ylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt (MTS) assay (CellTiter 96; Promega,Madison,WI,
USA).
For experiments cells were grown N70% conﬂuence and then made
quiescent by incubation in glucose-free RPMI 1640 supplemented
with 4 mM D-glucose with no serum for 24 h to induce cell cycle syn-
chronization and quiescence prior to treatment. All experiments were
done in serum free medium. Supplementing glucose-free RPMI 1640
with 30 mM D-glucose simulated hyperglycemic conditions. L-glucose,
the metabolically inactive stereoisomer of D-glucose, was added to
4mMD-glucosemedia at a concentration of 26mMto act as an osmotic
control for hyperglycemic media. Cells were grown in these conditions
for 48 h without a medium change, before collection of supernatants
for MCP-1 quantiﬁcation (below) or cell monolayer lysates for protein
extraction.
The effects of a selective P2X7R inhibitor (A438079; http://
www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=
biology&ligandId=4118; Tocris Bioscience, Bristol, UK), a P2X7R ag-
onist BzATP, (Tocris), on MCP-1 production were tested both in the
presence and absence of hyperglycemia by supplementing 4 mM
D-glucose and 30 mM D-glucose media respectively, with the ap-
propriate reagent concentration. Cells were treated for 30 min be-
fore collecting supernatants.
2.4. Protein Extraction
Cells were washed twice with ice-cold PBS before adding 100 μl of a
proprietary cell lysis buffer (Invitrogen; Constituents: 10 mM Tris
pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM
Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5%
deoxycholate) supplementedwith 1mMphenylmethanesulfonylﬂuoride
(PMSF; a serine protease inhibitor) and protease inhibitor cocktail
(P2714, Sigma Aldrich, Poole, UK). Monolayers were agitated for 2–
3 min before scraping and collecting the lysate into microcentrifuge
tubes. Tubes were rested on ice for 30 min, vortexing at 10 minute inter-
vals, to ensure complete lysis of cellmembranes and solubilization of pro-
teins. The extract was then centrifuged at 18,000 ×g for 10 min at 4oC to
pellet insoluble cellular debris. Supernatant was transferred to a fresh
microcentrifuge tube and protein concentration quantiﬁed (Pierce BCA
kit, Thermo Fisher Scientiﬁc).
2.5. Immunoﬂuorescent Staining of P2X7R in pHMC
Medium was removed and cells washed twice with PBS (Sigma-
Aldrich, Poole, UK). Cells were ﬁxed in 4% paraformaldehyde (PFA;
Sigma-Aldrich, Poole, UK) in PBS for 5 min at room temperature and
washed 3 times with PBS. Cells were permeabilized with 1 ml 0.1% Tri-
ton X-100 (Sigma-Aldrich) in PBS for 10 min and washed twice with
PBS.
Non-speciﬁc binding sites were blocked by incubation with 5% BSA
in 0.1% Triton in PBS for 1 h at room temperature. Primary P2X7R anti-
body (Ab109246; Abcam, RRID: AB_10858498, Cambridge, UK) or
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in PBS (Marvel; Premier Foods, St Albans, UK) was applied overnight.
Cells were then washed 3 times in PBS for 5 min each and incubated
with a ﬂuorochrome-conjugated secondary antibody (Alexa 488;
Invitrogen, Paisley, UK) diluted in 5% BSA in 0.1% Triton in PBS for 1 h
in the dark. Cells were washed with PBS, nuclei visualized with DAPI
(Vector Laboratories, Peterborough, UK).
2.6. Quantiﬁcation of pHMC MCP-1
A 96-well plate (Nunc ‘Maxisorp’, Thermo Fisher Scientiﬁc) was
coated with 100 μl of an afﬁnity-puriﬁed mouse anti-humanMCP-1 an-
tibody (R&DSystems, Abingdon, UK) at a concentration of 2 μg/ml dilut-
ed in PBS. The plate was covered with an adhesive strip (Appleton
Woods, Birmingham, UK) and placed at 4oC overnight to allow adsorp-
tion of antibody to the walls of the microplate. Recombinant human
MCP-1 (R&D Systems) was used to create a reference concentration se-
ries to form a 9-point standard series (9.76–2500 pg/ml). A ‘blank’ sam-
ple comprising diluent alonewas also included. Followingwashingwith
buffer, an afﬁnity-puriﬁed biotinylated polyclonal goat anti-human
MCP-1 antibody (100 ng/ml; R&D systems, Minneapolis, MN, USA)
was added and signal ampliﬁcation performed with streptavidin-HRP
conjugate. MCP-1 intensity was measured by absorbance (450 nm) in
the presence of 3,3′,5,5′-tetramethylbenzidine (TMB; Cambridge Biosci-
ence, Cambridge, UK) in an ELx800 spectrophotometric microplate
reader (BioTek, Winooski, VT, USA).
2.7. Animals
Home Ofﬁce Science Unit licensed all animal procedures under the
Animals (Scientiﬁc Procedures) Act 1986. Mice and rats were main-
tained in a pathogen-free animal facility at Imperial College London
(Hammersmith Hospital campus) in individually ventilated cages with
free access to water and standard laboratory diet. Maximum cage occu-
pancywasﬁvemiceper cage. All experimental animalsweremale. Gene
targeted or littermate control mice were on the C57BL/6 background.
P2X7R-deﬁcientmice (Ke et al., 2003) were bred in-house from hetero-
zygote breeding pairs provided by GlaxoSmithKline (GSK, Brentford,
UK); with littermate, wild-type (WT) animals used as experimental
controls. Notably this is a “knock-down” model in which the protein
coding murine P2X7k alternative transcript is expressed (Nicke et al.,
2009). Indeed, background P2X7R mRNA signal was detected in
P2X7R-deﬁcient mice, attributed to primer binding of these alternative
transcripts. Genotype PCR was performed using oligonucleotide
primers designed to discriminate between native (5′-3′: TGCCC
ATCTTCTGAACACC; 5′-3′: CTTCCTCTTACTGTTTCCTCCC) and disrupted
(5′-3′: TGCCCATCTTCTGAACACC; 5′-3′: GCAAGGCGATTAAGTTGGG)
forms of the P2rx7 gene.
2.8. Type 1 Diabetic Murine Model
WTand P2X7R-deﬁcientmice aged 8months or olderwere random-
ly divided into two groups: receiving either streptozotocin (STZ; Sigma-
Aldrich, Poole, UK) 50 mg/kg IP dissolved in 100 mM sodium citrate
buffer at pH 4.5 (n = 8), or citrate buffer alone (n = 8). STZ injections
were performed on 5 consecutive days, initially after a 4–6 hour fast
(DiaComp repetitive low-dose protocol (mouse)). Blood glucose (BG)
was measured 3 weeks after the last injection. Mice were immobilized
in a restrainer, a tail vein ‘prick’ performed with a 23G needle and a
OneTouch glucometer (Lifescan, Milpitas, CA, USA) used for glucose
measurement. BG N16 mmol/l was regarded as diabetic. BG was mea-
sured at additional 3 weekly intervals during the study, and animals
with readings falling outside of the desired range were excluded.
Urine was collected at baseline and week 12; terminal collection of
blood and kidney tissues was performed at week 12.2.9. Serum and Biochemical Analysis
The concentration of urinary albumin in mice wasmeasured using a
speciﬁc, indirect sandwich ELISA (Bethyl Laboratories,Montgomery, TX,
USA). Urinary albumin concentration values (transformed from ODs
using the standard curve and expressed inmg/l) were divided by paired
urinary creatinine to give the urine albumin to creatinine ratio (uACR;
mg/mmol creatinine). Urinary creatinine was measured using the Jaffe
reaction. Alkaline picrate was produced by adding 2.5 ml of 1 N sodium
hydroxide to 12.5 ml of picric acid against standards (0.03125–
2 mmol/l) in duplicate and measured at 490 nm (ELx800; BioTek,
Potton, UK). Serum creatinine was measured from whole blood
supernatant (centrifugation at 240 ×g for 5 min). Creatinine was mea-
sured by the modiﬁed Jaffe reaction in an Olympus AU600 analyzer
(Olympus, Watford, UK) by the clinical biochemistry laboratory at the
Hammersmith Hospital (London, UK).
2.10. Quantiﬁcation of Tissue Histology
Glomerular sizewasmeasured on periodic acid-Schiff (PAS)-stained
sections. Working systematically from one corner of the tissue section,
the ﬁrst 30 glomeruli encountered were digitized using a scientiﬁc
grade digital color camera (Olympus, Tokyo, Japan) at 400×magniﬁca-
tion. Scale was calibrated using an etched graticule of known diameter.
Subsequent image analysis was performed using ImagePro software
(Media Cybernetics, Bethesda, MD, USA). Glomeruli were carefully
outlined and each glomerular tuft isolated for surface area calculation.
At least 30 glomerular areas were calculated from each animal.
Tissue injury was assessed on Picrosirius red-stained sections to
detect collagen under polarized light. For each section, 5 randomly
selected cortical ﬁelds were photographed and digitized at 200× mag-
niﬁcation. Blood vessels larger than neighboring tubuleswere systemat-
ically excluded from selected ﬁelds to prevent skewing of results due to
the collagenous component of vessel walls. Using ImagePro, images
were converted to gray-scale, rendering birefringent collagen ﬁbrils
light gray or white. Picrosirius red-stained areas were highlighted auto-
matically. The highlighted area could then be measured and expressed
as a fraction of the area of the section. The mean value for 5 cortical
ﬁelds of view was calculated for each animal.
2.11. Rat Uninephrectomy
Right uninephrectomy (UNx; n = 25) or sham surgery (Sham; n =
8) was performed on male Wistar Han IGS rats (Crl:WI (Han); Charles
River; Margate, UK) weighing 200–250 g. Rats were anaesthetised
with a 1.5–2% isoﬂurane oxygen mix containing 0.5 l/min air. The
right ﬂank was shaved and a small incision made to expose the kidney.
The adipose capsule of the kidney was removed to provide access for a
cross-clamp placed over the vascular pedicle and ureter. A silk tie was
used to ligate the vessels and ureter proximal to the clamp and the kid-
ney removed. The clamp was removed and the muscle layer sutured
closed using an absorbable stitch in a continuous pattern; 3–4 clips
were applied to the skin. A second group of rats underwent sham ne-
phrectomy following the procedure described above but with both kid-
neys left in situ. Rats received a single subcutaneous dose of
buprenorphine analgesia (0.02 mg/kg) at the end of the operation.
Enroﬂoxacin (Baytril; Bayer, Leverkusen,Germany)was added to drink-
ing water for 48 h post-operatively as antibiotic prophylaxis against
wound infection.
2.12. Induction and Maintenance Streptozotocin-induced Diabetes in Rats
Two weeks after surgery, rats were randomly selected to receive a
single intravenous (IV) injection of STZ (40 mg/kg) or citrate buffer ve-
hicle. STZ was dissolved in 100 mmol/l citrate buffer (pH 4.5) at the
point of use. Animals were placed under light anaesthesia with
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nile vein. Water in drinking bottles was replaced with 10% sucrose for
48 h after injection to combat the risk of early hypoglycaemia due to in-
sulin release from injured beta cells.
Venous blood glucose (BG) was checked at 1 week post-injection
using a OneTouch glucometer (Lifescan, Milpitas, CA, USA). Light anaes-
thesia was induced with isoﬂuorane and a tail vein prick performed
with a 23G needle. Animals with a blood glucose of N33.3 mmol/l
were administered slow-release subcutaneous insulin pellets (Linshin,
Toronto, Canada) to prevent ketoacidosis. 1/8 insulin pellet provides ap-
proximately 0.25 units insulin per day. BGwas retested 1 week after in-
sertion and a further 1/8 pellet inserted if BG was persistently
N33.3 mmol/l. This cycle was continued until BG had been titrated
equivalently amongst experimental rats.
2.13. Administration of a Highly Selective P2X7R Inhibitor to Diabetic Rats
Following the establishment of diabetes at week 8, rats were ran-
domly allocated to receive either drug vehicle (UNx STZ Veh; n = 8),
or P2X7R inhibitor (P2X7Ri) at either 10 mg/kg (n = 8) or 50 mg/kg
(n = 9). The doses of the P2X7Ri (AZ11657312; www.
guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=
7722) were based on previous in vivo ﬁndings (Broom et al., 2008).
AZ11657312 was dissolved in a vehicle of 5% DMSO 95% 2-hydroxypro-
pyl-beta-cyclodextrin (HPBCD) solution. HPBCD was reconstituted as a
20% solution in distilledwater. Injection volumes for vehicle-treated an-
imalswere calculated to ensureweight-based equivalence to both treat-
ment groups. P2X7Ri or vehicle injections were administered IP twice
daily for 4 weeks. Urine collections were made at baseline and
12 weeks in metabolic cages. Following the ﬁnal urine collection, rats
were placed under terminal isoﬂurane anaesthetic and tissues collected
post exsanguination.
2.14. Statistics
All values described in the text and ﬁgures are expressed as mean±
standard error unless otherwise stated. Statistical comparisons were
carried out in GraphPad Prism (GraphPad Software, San Diego, CA,
USA). Numerical data comparing two groups were analyzed by the
Student's t-test for parametric data and Mann-Whitney U test for non-
parametric data. Categorical data comparing two groups were analyzed
with Fisher's exact test. Data comparingmore than two groupswere an-
alyzed by one-way ANOVA with post-tests corrected by the Bonferroni
method formultiple comparisons for parametric data, andKruskal-Wal-
lis with Dunn's post-test for non-parametric data. P b 0.05 was consid-
ered signiﬁcant.
3. Results
3.1. Renal P2X7R Expression is Associated With CKD and Fibrosis in
Diabetes
In renal biopsy sections from diabetic patients, P2X7R immuno-
localized to glomeruli (16/30; 53% patients), either as granular circum-
ferential endothelial deposits in capillary loops or more focally within
the glomerular mesangium (Fig. 1). The intensity of glomerular P2X7R
staining varied between glomeruli and interstitial compartments
(Suppl. Fig. 1a-c). The renal tubules stained positively for P2X7R across
the majority (27/30; 90%) of patients. In contrast, no glomerular or in-
terstitial P2X7R staining was observed in biopsies from patients with
TBM disease, which served as non-diabetic controls (Suppl. Fig. 2a).
Marked P2X7R expression was seen in a subset of tubular epithelial
cells with characteristics of the distal tubule (thin cuboidal epithelium
with little brush border and open lumens), while minimal proximal tu-
bular staining was seen (Suppl. Fig. 2b). However, non-diabetic P2X7R-
positive glomerular staining does occur in other human renal diseases,as indicated in the example of Class IV proliferative lupus nephritis
(Suppl. Fig. 2c).
Immunohistochemistry for the macrophage marker CD68 was per-
formed on two patient biopsies, one with signiﬁcant glomerular
P2X7R immunoreactivity and the other with predominantly
tubulointerstitial P2X7R expression (Fig. 1b). P2X7R staining appeared
more widespread than CD68, including endothelial glomerular struc-
tures. Most patients (23/30; 77%) also had evidence of P2X7R-positive
staining within the interstitial compartment (Fig. 1c) and in areas of
established tubular atrophy where a signiﬁcant number of inﬁltrating
inﬂammatory cells were apparent (Fig. 1d). Glomerular and interstitial
P2X7R staining was not mutually exclusive, co-existing in 11/30 or
37% of patients.
Renal function was assessed in TBM and a sub-set of the 23 diabetic
patients with distinct P2X7R interstitial or glomerular localization. Dia-
betic patients with only renal interstitial P2X7R staining (DNInt) had
signiﬁcantly lower estimated glomerular ﬁltration rate (eGFR) com-
pared with either patients with only glomerular P2X7R staining
(DNGlom) or with TBM control patients (Fig. 1e). Interstitial P2X7R
staining was also associated with more severe mesangial expansion in
patients with interstitial P2X7R staining with approximately half of
the tissue in this compartment undergoing interstitial ﬁbrosis (Fig.
1f); signiﬁcant expansion of the glomerular mesangium was also de-
tected in this group (Fig. 1g).
3.2. Glomerular Mesangial P2X7R Activation Enhances Monocyte
Chemoattraction
Glomerular mesangial cells attract circulating monocytes through
the release of chemoattractants such as MCP-1. Primary human
mesangial cells (pHMC's) were used to determine the role of P2X7R-
mediated MCP-1 release under high glucose conditions. In controls
(4mmol/l D-glucose), basal MCP-1 levels were not affected by addition
of the P2X7R agonist BzATP (Fig. 2a). Exposure of these cells to high glu-
cose (30 mmol/l D-glucose) induced a signiﬁcant increase in MCP-1 re-
lease (P b 0.05) and this effect was greatly ampliﬁed by P2X7R
activation (P b 0.0001). Notably, 30 mmol/l D-glucose did not change
total P2X7R expression in pHMC (Fig. 2b).
The P2X7R inhibitor A438079 completely prevented BzATP and high
glucose-induced secretion ofMCP-1 (Fig. 2c), with nodose-dependence
observed over the range 5-50 μM, (Suppl. Fig. 3). Importantly, A438079
did not impair cell viability (Suppl. Fig. 4). Comparison of nine indepen-
dent experimentswith normalization to baseline glucose levels demon-
strated a reproducible reduction in MCP-1 by A438079 (P b 0.05) (Fig.
2d).
3.3. P2X7R-deﬁciency Ameliorates Glomerular Damage in a Type I Diabetic
Mouse Model
Type I diabetes mellitus (T1DM) was induced inWT and P2X7R-deﬁ-
cient mice by injection of STZ. Three weeks after the ﬁnal injection, both
genotypes had developed similar levels of hyperglycemia, which also
maintained at 12 weeks (Fig. 2a). Plasma creatinine levels increased in
both groups following STZ treatment (Suppl. Fig. 5a). Urinary albumin-
creatinine levels were unchanged by induction of T1DM (Suppl. Fig. 5b).
T1DM increased whole kidney P2X7RmRNA expression inWTmice
(Fig. 3b) and glomerular P2X7R protein expressionwas also signiﬁcant-
ly increased (Fig. 3bi). This was not observed in P2X7R-deﬁcient mice
(Fig. 3bii). Tubular P2X7R-positive immunoreactivity was observed in
all sections, presumed to represent expression of an alternative splice
variant (P2X7Rk) in otherwise P2X7R-deﬁcient mice. Distinct intersti-
tial (non-tubular) staining was not observed. CD68-stained macro-
phages were increased in the glomeruli of diabetic wild-type mice and
macrophage accumulation was associated with increased deposition
of collagen. In contrast, P2X7R-deﬁcient mice were protected from the
diabetes-induced rise in glomerular macrophage number (Fig. 3c) and
Fig. 1.Renal P2X7R in humandiabetic nephropathy. Patient biopsies expressing (a) P2X7R protein and (b) CD68+monocytes in glomeruli indicatedwith black arrows. In themost severe
cases (c) P2X7R staining and (d) CD68+ staining of the interstitium overlapped in regions of inﬂammation. Estimated glomerular ﬁltration rate (eGFR) (e), ﬁbrosis (f) and mesangial
expansion (g) in patients with interstitial (DNInt = 7), glomerular (DNGlom= 5) P2X7R immunoreactivity compared to thin basement membrane (TBM= 3) controls subjects. *P b
0.05, **P b 0.01 DNint vs. TBM. a, b ×200 mag c, d ×100 mag.
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ident in CD68 stained glomeruli fromWT (Fig. 3ci) and P2X7R-deﬁcient
mice (Fig. 3cii). Glomerular macrophage accumulation was accompa-
nied by increased collagen IV deposition in WT mice (Fig. 3d, di),
which was not observed in P2X7R-deﬁcient mice (Fig. 3d, dii).
3.4. P2X7R Inhibition Ameliorates Macrophage Accrual in a Model of
Diabetic Nephropathy
Physical and biochemical data at baseline and week 12 are summa-
rized in Table 1. Body weights were similar in all groups at thebeginning of the experiment, while diabetic rats gained approximately
25% of the weight gained by control groups over the same period. Kid-
ney weight:body weight ratio more than doubled in UNx STZ Veh rats
compared with UNx Veh controls (P b 0.001) and increased by ~30%
compared with sham-operated and UNx controls (P b 0.001). Rats
treated with P2X7Ri had no change in kidney weight:body weight
ratio.
BG was similar across all groups at the beginning of the experiment
(Table 1). Hyperglycemia was stably maintained in diabetic animals by
insertion of insulin pellets such that hyperglycemia was tightly con-
trolled within the UNx STZ groups (Fig. 4a). Hyperglycemic levels
Fig. 2. Glomerular mesangial P2X7R andMCP-1. Activation of P2X7R with BzATP increased MCP-1 secretion from pHMCs under high glucose conditions (a). P2X7R protein expression in
mesangial cells under normal and high glucose conditions (b). Effect of a P2X7R inhibitor (A438079) onMCP-1 secretion (c). Subtraction of normal glucoseMCP-1 release highlighted the
absolute magnitude ofMCP-1 reduction by P2X7R blockade alone across 9 separate experiments (d). *P b 0.05, **P b 0.01, ***P b 0.001 vs baseline; †P b 0.05, ††P b 0.01, †††P b 0.01 versus
30 mM D pHMC; ‡‡‡‡P b 0.0001, 4 mM D + BzATP vs. 30 mM D+ BzATP.
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observations in P2X7R-deﬁcient mice where STZ injection caused hy-
perglycemia. Both terminal plasma creatinine and albumin excretion
rate (AER) were signiﬁcantly increased in the diabetic groups (Fig. 4b,
c). P2X7Ri did not reduce creatinine levels or albuminuria.
P2X7Rwas immunolocalized in renal sections. In control kidneys re-
moved at UNx, marked basolateral stainingwas observed in a subpopu-
lation of tubules and endothethial cells (Fig. 5a), but no signiﬁcant
glomerular positivity was detected. The remaining kidney was assessed
12 weeks later (UNx Veh) and a similar staining pattern was observed
(Fig. 5b). In the UNx STZ Veh group, P2X7Rwas highly expressed in glo-
meruliwheremarked capillary loop staining becamevisible (Fig. 5c) ad-
ditional constitutive expression of P2X7Rwas also detected in the distal
convoluted tubule. Antibody epitope speciﬁcity was demonstrated in a
UNx STZ Veh section (Fig. 5d).
Renal macrophage inﬁltration was assessed by CD68 immunolocal-
ization and quantiﬁed separately in glomerular and tubulointerstitial
compartments (Fig. 6). Interstitial macrophage number was increased
~50% in diabetic UNx rats compared with both sham-operated and
UNx controls (P b 0.05; Fig. 6a). Importantly, treatment with the
P2X7Ri reduced interstitial macrophage inhibition in diabetic UNx
rats, returning macrophage numbers to baseline levels. Representative
sections comparing sham kidneys (Fig. 6b), in which there were mini-
mal numbers of macrophages, and UNx STZ Veh kidneys (Fig. 6c)
showed interstitial macrophage accumulation in the UNx diabetic kid-
neys. P2X7Ri at 10 m/kg (Fig. 6d) was not sufﬁcient to reduce macro-
phage accumulation, however, 50 mg/kg was sufﬁcient (Fig. 6e). In
contrast to the interstitial compartment, glomerular macrophage num-
ber was not increased in diabetic rats compared with controls, and was
similar across all groups (Fig. 6f).4. Discussion
It is increasingly evident that P2X7R contributes to chronic inﬂam-
matory disorders: P2X7R activation promotes formation of the
cryopyrin (NLRP3) inﬂammasome and the release of cytokines
(Ferrari et al., 2006; Lister et al., 2007; Solle et al., 2001). P2X7R expres-
sion is increased inmodels of hypertension and diabetes (Ji et al., 2012a,
2012b; Menzies et al., 2015b; Vonend et al., 2004), both major risk fac-
tors for CKD in humans. Deletion or blockade of P2X7R protects against
antibody-induced glomerular injury (Taylor et al., 2009; Turner et al.,
2007) and deoxycorticosterone acetate salt-induced ﬁbrosis (Ji et al.,
2012b). Constitutively high renal P2X7R expression, impairs the pres-
sure-natriuresis response and enhances susceptibility to renal vascular
injury in rats (Menzies et al., 2013). Acute P2X7R antagonism improves
renal blood ﬂow, medullary perfusion and oxygenation in angiotensin-
II-induced hypertension (Menzies et al., 2015a).
In the present studywe found high P2X7R expression in renal biopsy
samples from patients with diabetic nephropathy. This is consistent
with detection of P2X7R in nephrectomy tissue from patients with
type 2 diabetes and renal cell carcinoma (Solini et al., 2013). Glomerular
expression of P2X7R was prevalent at ~50% in diabetes but was not ob-
served in TBM disease controls. P2X7R-deﬁcient mice were protected
from the STZ-induced glomerular damage observed in WT controls.
This suggests that many short-term preclinical models of increased glo-
merular P2X7R expression likely reﬂect early pro-inﬂammatory injury
found in human glomerulosclerosis. As such, P2X7R activation in the
renal vasculature or mesangium under hyperglycemic (Kreft et al.,
2016), or hypertensive (Conway et al., 2012;Menzies et al., 2015a) con-
ditions may also directly impair renal function in diabetic nephropathy.
Moreover, progression of diabetic nephropathy requires coordination of
Fig. 3. P2X7R-deﬁcient mice and STZ-induced glomerular macrophage accrual. Change in blood glucose following STZ injections (a). Renal P2X7 mRNA levels (b). Glomerular P2X7R
staining in WT (bi) and P2X7R-deﬁcient mice (bii). Glomerular macrophage accumulation following STZ (c). Glomerular CD68 staining in WT (ci) and P2X7R-deﬁcient mice (cii).
Glomerular type IV collagen deposition increased following STZ (d). Immunolocalization of lomerular collagen IV staining in WT (di) and P2X7R-deﬁcient mice (dii). *P b 0.05, **P b
0.01, ***P b 0.001. WT: wild-type. STZ: streptozotocin. KO: P2X7R-deﬁcient mice. b–d ×200 mag.
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from a combination of hyperglycemia and hypertension (Conway et
al., 2012). Indeed, more severe CKD and interstitial ﬁbrosis were
observed in biopsies in which there was high interstitial P2X7R expres-
sion and interstitial ﬁbrosis is typically found in more advanced disease
(Liu, 2011).
Our observations in patients and in vitro studies in pHMCs suggest
that activation of mesangial P2X7R may enhance early glomerularmacrophage recruitment leading to injury.MCP-1 attractsmacrophages
that promote pro-inﬂammatory processes (Conti and DiGioacchino,
2001; Rovin et al., 1994).We have previously demonstrated thatmacro-
phage accumulation is reduced in P2X7R-deﬁcient mice, as are urinary
MCP-1 levels (Taylor et al., 2009). Althoughmacrophages can transition
between pro- and anti- inﬂammatory phenotypes, depending on the
localmicroenvironment (Martinez andGordon, 2014), P2X7R preferen-
tially activates M1 polarized pro-inﬂammatorymacrophages (de Torre-
Table 1
Summary ofweight gain and baseline blood glucose in rats. Data from control (Sham and UNx Veh), diabetic (UNx STZ Veh) and P2X7Ri groups at doses stated.Measurementsweremade
at 0 and 12 weeks.
Sham (n = 8) UNx Veh (n = 8) UNx STZ Veh (n = 8) P2X7Ri (10 mg/kg; n = 8) P2X7Ri (50 mg/kg; n = 9)
Wk 0 Weight (g) 223.8 ± 12.5 218.8 ± 17.2 217.2 ± 13.3 215.3 ± 7.4 224.4 ± 10.3
% weight gain (Wk 0 to Wk12) 84.0 ± 15.8 84.9 ± 18.7 18.5 ± 8.6a,b 23.3 ± 6.1a,b 25.0 ± 10.8a,b
Wk 0
BG (mmol/l)
4.8 ± 0.8 5.8 ± 0.8 5.1 ± 0.6 5.7 ± 1.5 6.0 ± 1.1
Kidney weight: body weight (mg/kg) 2.70 ± 0.29 3.95 ± 0.23c 8.17 ± 0.85a,b 7.88 ± 0.89a,b 7.24 ± 0.98a,b
a,b P b 0.001 vs Sham or UNx Veh.
c P b 0.01 vs Sham.
80 R.I. Menzies et al. / EBioMedicine 19 (2017) 73–83Minguela et al., 2016); therefore, P2X7R activation promotes the accu-
mulation of deleterious pro-inﬂammatory macrophages.
Preclinical models of P2X7R-deﬁciency do not fully recapitulate the
clinical reality found in patients. However, the P2X7R-deﬁcient mouse
model did allow us to demonstrate that lack of canonical P2X7R does
not prevent STZ-induced hyperglycemia. Instead, P2X7R-deﬁciency ap-
pears to protect the kidney since these mice had reduced macrophageFig. 4. Effect of P2X7R inhibitor on blood glucose levels and kidney function. Blood glucose mea
excretion rate (AER) (c). *P b 0.05 UNx STZ groups vs. Sham or UNx Veh. ****P b 0.0001 UNx Saccrual and collagen IV deposition indicating, protection against expan-
sion of extracellular matrix, a hallmark of ﬁbrosis, in WT mice.
The P2X7Ri had signiﬁcant effectiveness in reducing renal macro-
phage accrual following the establishment of diabetes. Reduction of
renal interstitial macrophages with a P2X7Ri may be therapeutically
beneﬁcial in the longer-term in human diabetic nephropathy, since
we identiﬁed that these patients have more severe CKD and ﬁbrosis.sured at week 12 (a). Serum creatinine concentration in terminal serum (b) and albumin
TZ groups vs. Sham or UNx Veh. Measurements were made at 12 weeks.
Fig. 5. Immunolocalization of P2X7R in rat kidney. Normal Wistar Han kidney collected during UNx (a). Kidney tissue from a week 12 vehicle-injected UNx Wistar Han rat (b).
Representative P2X7R staining in a UNx STZ Veh rat kidney at week 12 (c). P2X7R staining in and STZ injected UNx rat where anti-P2X7 antibody was pre-absorbed with its conjugate
peptide (1:1) to demonstrate antibody speciﬁcity (d). a–d ×200 mag.
81R.I. Menzies et al. / EBioMedicine 19 (2017) 73–83An important limitation of this model was the lack of more severe glo-
merular and tubulointerstitial damage seen in humandiabetic nephrop-
athy. Indeed, glomerular macrophage accrual was never increased in
the rat model. This may be unsurprising however, since many preclini-
cal kidney disease models fail to capture the severity of human disease
(Mullins et al., 2016). The lack of impact of P2X7R blockade on albumin
excretion is consistentwith the experimental ﬁndings in the P2X7R-de-
ﬁcientmice and suggests that P2X7R does have an importantmechanis-
tic role in the early development of glomerular damage and
albuminuria; although this is despite apparent upregulation of P2X7R
in the glomeruli at 12weeks in bothmice and rats with STZ-induced di-
abetes. Collectively, this study demonstrates the potential for selective
P2X7Ri to reduce renalmacrophage accumulation, supporting future in-
vestigations of P2X7R inhibition in diabetes and other renal diseases
characterized by macrophage inﬁltration.
Prophylactic use of a P2X7Ri has proven reno-protective in multiple
kidney disease models (Menzies et al., 2016), but it is unclear whether
blockade can reverse an established ﬁbrotic phenotype. The data pre-
sented here suggest that P2X7Ri may have speciﬁc anti-inﬂammatory
and anti-macrophage role in diabetic nephropathy. Further longitudinal
studies are required to determinewhether P2X7Ri can offer real clinical
beneﬁt to early, and more established ﬁbrotic kidney disease in diabe-
tes, as well as other forms of human CKD.
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